指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛儿科与产科急症

慢加急性肝衰竭:亚太肝病学会(APASL)共识建议更新

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.
指南 / 共识 · Hepatol Int · 2019-06-06
一句话结论APASL基于约5200例AARC前瞻性数据更新ACLF共识,原定义仍适用,并提出凝血障碍、肾脏替代、脓毒症、静脉曲张出血、抗病毒及肝移植标准等新管理路径。

本文为亚太肝病学会(APASL)慢加急性肝衰竭(ACLF)共识更新。2009年首版共识后,2012年成立APASL ACLF研究协作组(AARC),2014年基于近1400例前瞻性数据发布共识;近四年半来AARC数据库扩展至约5200例。2018年10月新德里会议采用Grade系统、仅接受基于证据且一致推荐的声明,并经2018年11月AASLD会议AARC研究者会议修订。共识认为原ACLF定义经得起时间检验,能识别同质性肝衰竭患者群,并提出凝血障碍、肾脏替代治疗、脓毒症、静脉曲张出血、抗病毒及肝移植标准等管理路径。

要点

  • APASL ACLF原定义经约5200例AARC前瞻性数据检验,仍能识别同质性肝衰竭患者群。
  • 共识仅纳入基于Grade系统证据且一致推荐的声明,经2018年10月新德里会议定稿。
  • 新管理路径包括凝血障碍管理流程、肾脏替代治疗、脓毒症、静脉曲张出血及抗病毒治疗。
  • 共识提出ACLF患者肝移植标准。
  • AARC数据库用于分析肝衰竭分级及其对「黄金治疗窗口」的影响、肝外器官功能障碍与衰竭、脓毒症发生、急性失代偿与ACLF的鉴别特征及儿童ACLF。

适用人群与场景

  • 慢加急性肝衰竭(ACLF)患者,包括儿童ACLF。

诊断标准与关键阈值

  • APASL ACLF原定义经AARC约5200例前瞻性数据检验,仍能识别同质性肝衰竭患者群。

处置流程与药物剂量

  • 提出凝血障碍管理流程。
  • 提出肾脏替代治疗管理路径。
  • 提出脓毒症管理路径。
  • 提出静脉曲张出血管理路径。
  • 提出抗病毒治疗管理路径。
  • 提出ACLF患者肝移植标准。

研究设计与关键结果

  • 制定机构:亚太肝病学会(APASL)ACLF工作小组;方法:AARC前瞻性数据库约5200例,采用Grade系统证据分级,仅接受基于证据且一致推荐的声明,2018年10月新德里会议定稿,2018年11月AASLD会议AARC研究者会议修订。

证据类型、等级与局限

  • 证据类型:指南/共识;采用Grade系统证据分级,仅纳入基于证据且一致推荐的声明。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 共识认为原ACLF定义经得起时间检验,能识别同质性肝衰竭患者群。
  • 共识提出凝血障碍、肾脏替代治疗、脓毒症、静脉曲张出血、抗病毒及肝移植标准等新管理选项,供临床参考。

指南或共识出处

  • 亚太肝病学会(APASL)慢加急性肝衰竭共识建议更新,发表于Hepatol Int。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. With international groups volunteering to join, the "APASL ACLF Research Consortium (AARC)" was formed in 2012, which continued to collect prospective ACLF patient data. Based on the prospective data analysis of nearly 1400 patients, the AARC consensus was published in 2014. In the past nearly four-and-a-half years, the AARC database has been enriched to about 5200 cases by major hepatology centers across Asia. The data published during the interim period were carefully analyzed and areas of contention and new developments in the field of ACLF were prioritized in a systematic manner. The AARC database was also approached for answering some of the issues where published data were limited, such as liver failure grading, its impact on the 'Golden Therapeutic Window', extrahepatic organ dysfunction and failure, development of sepsis, distinctive features of acute decompensation from ACLF and pediatric ACLF and the issues were analyzed. These initiatives concluded in a two-day meeting in October 2018 at New Delhi with finalization of the new AARC consensus. Only those statements, which were based on evidence using the Grade System and were unanimously recommended, were accepted. Finalized statements were again circulated to all the experts and subsequently presented at the AARC investigators meeting at the AASLD in November 2018. The suggestions from the experts were used to revise and finalize the consensus. After detailed deliberations and data analysis, the original definition of ACLF was found to withstand the test of time and be able to identify a homogenous group of patients presenting with liver failure. New management options including the algorithms for the management of coagulation disorders, renal replacement therapy, sepsis, variceal bleed, antivirals and criteria for liver transplantation for ACLF patients were proposed. The final consensus statements along with the relevant background information and areas requiring future studies are presented here.

来源:Hepatol Int,查看原文。版权归原作者所有。

参考来源

  1. Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019. PMID: 31172417. doi:10.1007/s12072-019-09946-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。